Skip to main content

Advertisement

SpringerLink
Log in

Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Paclitaxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC).

Methods

One hundred and seven patients with locally advanced or metastatic gastric adenocarcinoma received intravenous infusions of PTX at 135 mg/m2 and OXA at 85 mg/m2 on day 1 every 14 days.

Results

Among 107 patients enrolled, 9 patients could not be evaluated for a response because of the absence of any measurable lesions. Assessment of the response of 98 patients was made. The overall objective response rate was 42.9% (95% CI 32.9–52.8%), with two complete responses and 40 partial responses. The disease control was 79.6% (95% CI 71.5–87.7%). With 29 months of the median time of follow-up, the median progression-free survival was 5.8 months (95% CI 4.30–7.30 months) and the median overall survival was 11.5 months (95% CI 9.08–13.9 months). The 1-year survival rate was 48.0%. The most common grades 3 and 4 toxicities included neutropenia (32.7%), leucopenia (17.8%), fatigue (5.61%), and anemia (4.67%). Peripheral neuropathy occurred in 23.4% patients and grade 2 or higher peripheral neuropathy occurred in 12.1% of the patients.

Conclusions

Combination chemotherapy with PTX and OXA offers a new, effective and safe regimen for patients with advanced gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64 (1):9–29. https://doi.org/10.3322/caac.21208

    Article  PubMed  Google Scholar 

  2. Zhao P, Dai M, Chen W, Li N (2010) Cancer trends in China. Jpn J Clin Oncol 40 (4):281–285. https://doi.org/10.1093/jjco/hyp187

    Article  PubMed  Google Scholar 

  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249. https://doi.org/10.3322/caac.20006

    Article  PubMed  Google Scholar 

  4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8(2):163–168

    Article  PubMed  CAS  Google Scholar 

  5. Imamura Y, Yoshimi I (2005) Comparison of cancer mortality (stomach cancer) in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960–2000). Jpn J Clin Oncol 35(2):103–105. https://doi.org/10.1093/jjco/hyi030

    Article  PubMed  Google Scholar 

  6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991–4997.https://doi.org/10.1200/jco.2006.06.8429

    Article  PubMed  Google Scholar 

  7. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46. https://doi.org/10.1056/NEJMoa073149

    Article  PubMed  CAS  Google Scholar 

  8. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221. https://doi.org/10.1016/s1470-20145(08)70035-4

    Article  PubMed  CAS  Google Scholar 

  9. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V (2003) Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 3(4):291–306

    Article  PubMed  CAS  Google Scholar 

  10. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T (1998) An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21(4):416–419

    Article  PubMed  CAS  Google Scholar 

  11. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T (2001) Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12(8):1133–1137

    Article  PubMed  CAS  Google Scholar 

  12. Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y (2013) Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin 29(2):117–125. https://doi.org/10.1185/03007995.2012.756393

    Article  PubMed  CAS  Google Scholar 

  13. Eriguchi M, Nonaka Y, Yanagie H, Yoshizaki I, Takeda Y, Sekiguchi M (2003) A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines. Biomed Pharmacother 57(9):412–415

    Article  PubMed  CAS  Google Scholar 

  14. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jager E (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9):1435–1442. https://doi.org/10.1200/jco.2007.13.9378

    Article  PubMed  CAS  Google Scholar 

  15. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J (2005) Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 92 (11):1976–1983. https://doi.org/10.1038/sj.bjc.6602572

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Gu J, Yamamoto H, Lu X, Ngan CY, Tsujino T, Konishi K, Takemasa I, Ikeda M, Nagata H, Hashimoto S, Matsuzaki T, Sekimoto M, Takagi A, Monden M (2006) Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines. Digestion 74(1):19–27. https://doi.org/10.1159/000095826

    Article  PubMed  CAS  Google Scholar 

  17. Guo Z, Wang X, Lin R, Chen L, Fan N, Chen Y, Lin J, Yu J (2015) Paclitaxel-based regimens as first-line treatment in advanced gastric cancer. J Chemother 27(2):94–98. https://doi.org/10.1179/1973947814y.0000000169

    Article  PubMed  CAS  Google Scholar 

  18. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol Off J Am Soc Clin Oncol 24(18):2903–2909. https://doi.org/10.1200/jco.2005.05.0245

    Article  CAS  Google Scholar 

  19. Lv F, Liu X, Wang B, Guo H, Li J, Shen L, Jin M (2014) S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil. Int J Clin Exp Pathol 7(7):4274–4279

    PubMed  PubMed Central  CAS  Google Scholar 

  20. Kim JG, Sohn SK, Song HS, Kwon KY, Do YR, Lee KH, Hyun MS, Ryoo HM, Bae SH, Park KU, Baek JH, Lee WS, Chung JS, Cho GJ, Sohn CH, Jang JS, Chung HY, Yu W (2007) Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 60(6):863–869. https://doi.org/10.1007/s00280-007-0433-8

    Article  PubMed  CAS  Google Scholar 

  21. Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C (2002) Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 13(5):497–503

    Article  PubMed  CAS  Google Scholar 

  22. Lokich JJ, Sonneborn H, Anderson NR, Bern MM, Coco FV, Dow E, Oliynyk P (1999) Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer 85(11):2347–2351

    Article  PubMed  CAS  Google Scholar 

  23. Sakamoto J, Matsui T, Kodera Y (2009) Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer 12(2):69–78. https://doi.org/10.1007/s10120-009-0505-z

    Article  PubMed  CAS  Google Scholar 

  24. Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, Tanabe S, Higuchi K, Sasaki T, Sekikawa T (2009) Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial. Jpn J Clin Oncol 39(11):713–719. https://doi.org/10.1093/jjco/hyp099

    Article  PubMed  Google Scholar 

  25. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol Off J Eur Soc Med Oncol 26(1):141–148. https://doi.org/10.1093/annonc/mdu472

    Article  CAS  Google Scholar 

  26. Lee HH, Hur H, Kim SH, Park AR, Kim W, Jeon HM (2010) Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat 42(1):18–23. https://doi.org/10.4143/crt.2010.42.1.18

    Article  PubMed  PubMed Central  Google Scholar 

  27. Kim HS, Kim JH, Kim HJ, Jang HJ, Kim JB, Kim JW, Jung SY, Kim BC, Yang DH, Park S, Kim KJ, Lee SI, Zang DY (2012) Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett 3(2):425–428. https://doi.org/10.3892/ol.2011.496

    Article  PubMed  CAS  Google Scholar 

  28. Shi C, Chen Q, Shen S, Wu R, Yang B, Liu Q, Xu Q (2015) Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer. Expert Rev Anticancer Ther 15(5):595–601. https://doi.org/10.1586/14737140.2015.1026807

    Article  PubMed  CAS  Google Scholar 

  29. Cunningham D, Okines AF, Ashley S (2010) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 362 (9):858–859. https://doi.org/10.1056/NEJMc0911925

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We wish to thank all the patients who volunteered for this study and the staff of Fujian Medical University Tumor Research Center who contributed to it. We also thank Mr. Cai Dingnan for his assistance in the statistical analysis.

Funding

This study was funded by the Foundation of Medical Innovation Project in Fujian Province (Grant no. 2016-CX-26).

Author information

Author notes

  1. Yan-qin Lan and Ling-jun Kong contributed equally to this work.

Authors and Affiliations

  1. Department of Medical Oncology, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, Fujian, People’s Republic of China

    Yan-qin Lan, Xiao-yan Lin, Qian Xu, Xin-yan Gao, Ri-ping Wu, Xin-li Wang & Dong-ta Zhong

  2. Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, 350001, Fujian, People’s Republic of China

    Yan-qin Lan, Xiao-yan Lin, Qian Xu, Xin-yan Gao, Ri-ping Wu, Xin-li Wang & Dong-ta Zhong

  3. Fujian Medical University Stem Cell Research Institute, Fuzhou, 350001, Fujian, People’s Republic of China

    Yan-qin Lan, Xiao-yan Lin, Qian Xu, Xin-yan Gao, Ri-ping Wu, Xin-li Wang & Dong-ta Zhong

  4. Department of Thyroid and Breast Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, Fujian, People’s Republic of China

    Ling-jun Kong

Authors
  1. Yan-qin Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ling-jun Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-yan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qian Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xin-yan Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ri-ping Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xin-li Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dong-ta Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong-ta Zhong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lan, Yq., Kong, Lj., Lin, Xy. et al. Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Cancer Chemother Pharmacol 81, 1007–1015 (2018). https://doi.org/10.1007/s00280-018-3576-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-018-3576-x

Keywords

Search

Navigation